[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 12515
1. Kaira K, Ishizuka T, Tanaka H, Tanaka Y, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M: B-cell non-Hodgkin lymphoma presenting as an endobronchial polypoid mass. J Thorac Oncol; 2008 May;3(5):530-1
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell non-Hodgkin lymphoma presenting as an endobronchial polypoid mass.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449008.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Mancuso P, Calleri A, Antoniotti P, Quarna J, Pruneri G, Bertolini F: If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer; 2010;10:644
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.
  • BACKGROUND: Staging of B-cell non Hodgkin's lymphoma (NHL) routinely involves bone marrow (BM) examination by trephine biopsy (BM-TB).
  • The evidence of disease in the BM-TB results in a clinical stage IV classification affecting therapeutic strategies for NHL patients.
  • BM immunophenotyping by flow cytometry (FC) is also used, although its clinical value is still under debate.
  • Aberrant immunophenotypes present in the B-cell subpopulation were also investigated.
  • Concordance was defined as the presence of a positive (in terms of disease detection) or negative result in both BM-FC and PB-FC or BM-TB and BM-FC.
  • Among the discordant cases (ie presence of neoplastic B-lymphocyte in the BM but under the sensibility of the technique in the PB) the most frequent diagnosis was Waldenstrom's macroglobulinemia (WM, accounting for 20.8% of all discordant cases).
  • The expression of CXCR4, a receptor involved in B-cell trafficking and homing, was found to be down regulated in WM compared to other NHL types, thus suggesting a possible role of CXCR4 in WM cell homing in the BM.
  • CONCLUSIONS: The finding that FC data from BM and PB samples overlap in NHL might have major implications for the design of future clinical studies and for patients' follow-up.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1460-9 [12145686.001]
  • [Cites] Histopathology. 2004 Sep;45(3):268-74 [15330805.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1336-42 [7751877.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):255-67 [16409290.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Eur J Clin Invest. 2007 Apr;37(4):305-9 [17373966.001]
  • [Cites] Leukemia. 2007 May;21(5):956-64 [17361231.001]
  • [Cites] Blood. 2008 Jul 1;112(1):150-8 [18448868.001]
  • (PMID = 21106070.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Receptors, CXCR4
  • [Other-IDs] NLM/ PMC2995803
  •  go-up   go-down


3. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood; 2006 May 1;107(9):3639-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
  • Most non-Hodgkin lymphomas (NHLs) are of B-cell origin, but the tumor tissue can be variably infiltrated with T cells.
  • In the present study, we have identified a subset of CD4(+)CD25(+) T cells with high levels of CTLA-4 and Foxp3 (intratumoral T(reg) cells) that are overrepresented in biopsy specimens of B-cell NHL (median of 17% in lymphoma biopsies, 12% in inflammatory tonsil, and 6% in tumor-free lymph nodes; P = .001).
  • We found that these CD4(+)CD25(+) T cells suppressed the proliferation and cytokine (IFN-gamma and IL-4) production of infiltrating CD4(+)CD25(-) T cells in response to PHA stimulation.
  • PD-1 was found to be constitutively and exclusively expressed on a subset of infiltrating CD4(+)CD25(-) T cells, and B7-H1 could be induced on intratumoral CD4(+)CD25(+) T cells in B-cell NHL.
  • Anti-B7-H1 antibody or PD-1 fusion protein partly restored the proliferation of infiltrating CD4(+)CD25(-) T cells when cocultured with intratumoral T(reg) cells.
  • Finally, we found that CCL22 secreted by lymphoma B cells is involved in the chemotaxis and migration of intratumoral T(reg) cells that express CCR4, but not CCR8.
  • Taken together, our results suggest that T(reg) cells are highly represented in the area of B-cell NHL and that malignant B cells are involved in the recruitment of these cells into the area of lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):834-42 [14707053.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85 [16001955.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4180-3 [16177055.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Immunol Rev. 2001 Aug;182:18-32 [11722621.001]
  • [Cites] Nat Immunol. 2001 Dec;2(12):1126-32 [11702067.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8643-6 [11751377.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):237-46 [12119348.001]
  • [Cites] Adv Immunol. 2003;81:331-71 [14711059.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):81-8 [15036231.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):816-22 [11526392.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):247-53 [12119349.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):255-60 [12119350.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):771-8 [12413528.001]
  • [Cites] J Allergy Clin Immunol. 2002 Nov;110(5):693-702 [12417876.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1335-46 [12438424.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6210-7 [12444126.001]
  • [Cites] J Clin Invest. 2003 Feb;111(3):363-70 [12569162.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] Curr Opin Immunol. 2003 Dec;15(6):690-6 [14630204.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • (PMID = 16403912.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, Surface; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Receptors, Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC1895773
  •  go-up   go-down


Advertisement
4. Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL: Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer; 2008 Nov 1;113(9):2496-503
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT).
  • The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy.
  • METHODS: Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included.
  • CONCLUSIONS: The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / therapy. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Fluorodeoxyglucose F18. Humans. Ifosfamide / administration & dosage. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radionuclide imaging. Lymphoma, Follicular / therapy. Male. Melphalan / administration & dosage. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Radiopharmaceuticals. Remission Induction. Salvage Therapy. Survival Analysis. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833583.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 04079A1RDZ / Cytarabine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Guan H, Xie L, Leithäuser F, Flossbach L, Möller P, Wirth T, Ushmorov A: KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood; 2010 Sep 2;116(9):1469-78
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma.
  • In T- and pre-B-cell lymphoma, KLF4 was found to act as tumor suppressor.
  • We found the KLF4 promoter methylated in B-cell lymphoma cell lines and in primary cases of B-cell lymphomas, namely, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and in classic Hodgkin lymphoma (cHL) cases.
  • Conditional overexpression of KLF4 in Burkitt lymphoma cell lines moderately retarded proliferation, via cell-cycle arrest in G(0)/G(1).
  • In the cHL cell lines, KLF4 induced massive cell death that could partially be inhibited with Z-VAD.fmk.
  • These genes are specifically up-regulated in HRS cells of cHL and known to be involved in establishing the cHL phenotype.
  • We conclude that epigenetic silencing of KLF4 in B-cell lymphomas and particularly in cHL may favor lymphoma survival by loosening cell-cycle control and protecting from apoptosis.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Genes, Tumor Suppressor. Hodgkin Disease / metabolism. Kruppel-Like Transcription Factors / physiology. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism
  • [MeSH-minor] Apoptosis. B-Lymphocytes / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Child. Child, Preschool. DNA Methylation. DNA, Neoplasm / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. bcl-2 Homologous Antagonist-Killer Protein / antagonists & inhibitors. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519630.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger; 0 / bcl-2 Homologous Antagonist-Killer Protein
  •  go-up   go-down


6. Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, Ziesmer S, Liebow M, Macon WR, Dillon SR, Witzig TE, Cerhan JR, Ansell SM: Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res; 2009 May 15;69(10):4217-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.
  • Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been found in patients with B-cell malignancies and autoimmune diseases, suggesting that it may play a pathogenic role.
  • We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non-Hogkin lymphoma (NHL) risk.
  • When categorized into low-, moderate-, and high-risk groups based on risk alleles, we found the permutation-corrected odds ratio for the trend to be 1.43 (P = 0.0019) for risk of B-cell NHL, 1.69 (P = 0.0093) for diffuse large B-cell lymphoma, 1.43 (P = 0.029) for follicular lymphoma, and 1.06 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Apr;97(1):107-12 [9136948.001]
  • [Cites] Arthritis Res Ther. 2006;8(1):R30 [16507129.001]
  • [Cites] Blood. 1998 May 15;91(10):3574-81 [9572991.001]
  • [Cites] Int Immunol. 1998 Nov;10(11):1693-702 [9846698.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):319-28 [15972664.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1021-30 [15827134.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):129-35 [10880534.001]
  • [Cites] Mamm Genome. 2000 Aug;11(8):628-32 [10920230.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):547-52 [10953976.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):59-68 [11781351.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Exp Hematol. 2002 Feb;30(2):135-41 [11823048.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Blood. 2002 Oct 15;100(8):3037-40 [12351419.001]
  • [Cites] Genes Immun. 2002 Nov;3(7):424-9 [12424625.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):439-40 [12665861.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):548-55 [12671023.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38220-8 [12867412.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):812-22 [14707051.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Immunity. 2004 Apr;20(4):441-53 [15084273.001]
  • [Cites] Blood. 2004 May 1;103(9):3529-34 [14701701.001]
  • [Cites] Am J Hematol. 2004 May;76(1):14-8 [15114591.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):829-34 [16007086.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):820-8 [16007087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3004-6 [16365026.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):983-7 [16432079.001]
  • [Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4540-8 [16497967.001]
  • [Cites] Blood. 2007 Jan 15;109(2):729-39 [16960154.001]
  • [Cites] Br J Haematol. 2007 Jan;136(2):309-14 [17156395.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5439-46 [17327408.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1869-71 [17786728.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3161-9 [18990758.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1489-96 [9338474.001]
  • (PMID = 19383901.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121569; United States / NCI NIH HHS / CA / R21 CA121569-02; United States / NCI NIH HHS / CA / CA121569-02; United States / NCI NIH HHS / CA / P50 CA097274-05; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA92153; United States / NCI NIH HHS / CA / CA092153-06; United States / NCI NIH HHS / CA / CA097274-05; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / CA097274; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092153-06; United States / NCI NIH HHS / CA / R21 CA121569
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / TNFSF13B protein, human
  • [Other-IDs] NLM/ NIHMS123245; NLM/ PMC2743448
  •  go-up   go-down


7. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS, FAB/LMB96 International Study Committee: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood; 2007 Apr 1;109(7):2773-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
  • A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases).
  • There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Remission Induction. Risk Factors. Survival Rate. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95 [1793154.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1396-402 [10780517.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):441-8 [11786572.001]
  • [Cites] Leukemia. 2002 Apr;16(4):594-600 [11960338.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):385-94 [15241838.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Sep;26(9):555-60 [15342981.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] J Chronic Dis. 1981;34(9-10):469-79 [7276137.001]
  • [Cites] J Chronic Dis. 1985;38(8):683-90 [4019705.001]
  • [Cites] J Clin Oncol. 1986 Aug;4(8):1219-26 [3525767.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):304-9 [2493074.001]
  • [Cites] Stat Med. 1989 Oct;8(10):1191-8 [2814068.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):526-33 [9324339.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • (PMID = 17132719.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol
  • [Other-IDs] NLM/ PMC1852229
  •  go-up   go-down


8. Schroeder T, Zohren F, Saure C, Kobbe G, Haas R: Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma. Bone Marrow Transplant; 2009 Dec;44(12):823-4
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Alphapapillomavirus. Condylomata Acuminata. Fibroblast Growth Factor 7 / adverse effects. HIV Seropositivity. Lymphoma, Large B-Cell, Diffuse


9. Tay K, Dunleavy K, Wilson WH: Novel agents for B-cell non-Hodgkin lymphoma: science and the promise. Blood Rev; 2010 Mar;24(2):69-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.
  • New molecular targets in neoplastic cells are emerging and provide the rationale for clinical development of novel agents in non-Hodgkin lymphoma.
  • The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy


10. Grubstein A, Givon-Madhala O, Morgenstern S, Cohen M: Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis. J Clin Ultrasound; 2005 Mar-Apr;33(3):140-2
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.
  • We report a case of primary, high-grade non-Hodgkin B-cell lymphoma in the breast of a young woman.
  • The clinical and sonographic presentation was not of a mass but of an infiltrating anechoic process mimicking mastitis.
  • Primary breast lymphoma is a rare entity, especially in young females.
  • In previous imaging reports of breast lymphoma, it has always been considered as a mass, though the presence of markedly hypoechoic regions that look like fluid collections is a well known sonographic characteristic of lymphoma.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography. Mastitis / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Mammary


11. Keller CE, Nandula S, Vakiani E, Alobeid B, Murty VV, Bhagat G: Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non-Hodgkin lymphoma. Hum Pathol; 2006 Aug;37(8):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non-Hodgkin lymphoma.
  • Balanced reciprocal translocations involving chromosomal region 3q27, which led to identification of the BCL6 protooncogene, are one of the most common recurrent chromosomal abnormalities reported in B-cell non-Hodgkin lymphomas (B-NHL).
  • Cloning of the breakpoints of these translocations has facilitated the identification of a number of BCL6 partners including immunoglobulin genes and more than 20 non-immunoglobulin genes on almost all human chromosomes.
  • These rearrangements accounted for 3/20 (15%) of all BCL6 translocations occurring in B-NHL, including follicular lymphomas, diffuse large B-cell lymphomas, and marginal zone B-cell lymphomas, diagnosed at our institute.
  • Our data should help facilitate the identification of new BCL6 partner genes, which may enhance our understanding of the clinical and biological role of BCL6 in B-NHL pathogenesis.
  • [MeSH-major] Chromosomes, Human, Pair 3. DNA-Binding Proteins / genetics. Gene Rearrangement. Lymphoma, B-Cell / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867873.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  •  go-up   go-down


12. Sikder MA, Friedberg JW: Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Oncol Rep; 2008 Sep;10(5):420-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.
  • The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells.
  • Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies.
  • The goal of these newer agents is to achieve similar or better response rates as seen with rituximab, and perhaps demonstrate activity in rituximab-refractory disease.
  • Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Immunotherapy / methods. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Epitopes / chemistry. Humans. Medical Oncology / methods. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706270.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Epitopes; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 37
  •  go-up   go-down


13. Aggarwal M, Sánchez-Beato M, Gómez-López G, Al-Shahrour F, Martínez N, Rodríguez A, Ruiz-Ballesteros E, Camacho FI, Pérez-Rosado A, de la Cueva P, Artiga MJ, Pisano DG, Kimby E, Dopazo J, Villuendas R, Piris MA: Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. Leuk Lymphoma; 2009 Oct;50(10):1699-708
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.
  • Gene-expression profiling in B-cell lymphomas has provided crucial data on specific lymphoma types, which can contribute to the identification of essential lymphoma survival genes and pathways.
  • In this study, the gene-expression profiling data of all major B-cell lymphoma types were analyzed by unsupervised clustering.
  • The transcriptome classification so obtained, was explored using gene set enrichment analysis generating a heatmap for B-cell lymphoma that identifies common lymphoma survival mechanisms and potential therapeutic targets, recognizing sets of coregulated genes and functional pathways expressed in different lymphoma types.
  • Some of the most relevant signatures (stroma, cell cycle, B-cell receptor (BCR)) are shared by multiple lymphoma types or subclasses.
  • A specific attention was paid to the analysis of BCR and coregulated pathways, defining molecular heterogeneity within multiple B-cell lymphoma types.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, B-Cell / genetics. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863341.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


14. Gupta S, Gupta R, Singh S, Gupta K, Kudesia M: Nuclear morphometry and texture analysis of B-cell non-Hodgkin lymphoma: utility in subclassification on cytosmears. Diagn Cytopathol; 2010 Feb;38(2):94-103
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and texture analysis of B-cell non-Hodgkin lymphoma: utility in subclassification on cytosmears.
  • Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid neoplasms and accurate subclassification is an essential prerequisite for proper management of patients.
  • Fine needle aspiration smears of 50 cases of B-cell NHL were included.
  • The percentage of cells correctly classified to a particular NHL subtype using the discriminant functions so obtained was noted.Our results show that discriminant analysis done on size parameters could correctly classify a greater number of cells than on shape parameters (36.4% vs. 21.2%, respectively).
  • Texture parameters based on single pixel values (first order texture) were inferior (42.8%) to those based on pair of pixels (58.7%) in subtyping of cells.
  • Using all the morphometric and textural parameters together, 83.3% of cells could be correctly classified to a particular NHL subtype.The present study, perhaps the first study of detailed morphometric analysis on cytosmears, shows that satisfactory classification of NHL on aspiration cytology is possible using nuclear morphometry and textural parameters considered together.
  • [MeSH-major] Cell Nucleus / ultrastructure. Cytodiagnosis / methods. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / ultrastructure

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688760.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


15. Visser OJ, Perk LR, Zijlstra JM, van Dongen GA, Huijgens PC, van de Loosdrecht AA: Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. BioDrugs; 2006;20(4):201-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
  • In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells.
  • Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).
  • Clinical experience with RIT in the treatment of patients with indolent NHL is increasing.
  • In general, there is no organ-specific non-hematologic toxicity when a standard dose of RIT is used.
  • RIT is feasible in heavily pretreated patients and does not compromise future treatments in the event of progressive disease.
  • Randomized phase III studies are in progress to evaluate the timing of RIT in the overall management of indolent NHLInvestigations of new emerging therapeutic strategies for patients with indolent NHL are underway, with research into the feasibility of RIT as first-line therapy and in advanced disease, RIT dose escalation and combined modality approaches with autologous stem cell transplantation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Disease Progression. Feasibility Studies. Humans. Models, Biological. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831019.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 42
  •  go-up   go-down


16. Sikder MA, Friedberg JW: Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Oct;3(4):187-93
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.
  • The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells.
  • Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies.
  • The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease.
  • Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Clinical Trials as Topic. Humans. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425465.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / PRO131921 monoclonal antibody; 0 / dacetuzumab; 0 / epratuzumab; 0 / ocrelizumab; 0 / ofatumumab; 0 / veltuzumab; 357613-77-5 / galiximab; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 37
  •  go-up   go-down


17. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M: Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol; 2009 May 20;27(15_suppl):8553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
  • : 8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells through mitosis.
  • In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab.
  • In two of the models (Ly19 & WSU) the tumor cells expressed a constitutively active luciferase, enabling tumor burden analysis in either a subcutaneous or disseminated setting.
  • In the primary lymphoma model, MLN8237(10-20mg/kg) caused a significant anti-tumor effect during treatment period (TGI = 83-95%).
  • MLN8237 is currently being tested as a single agent in a phase I clinical trail in patients with DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Li G Jr, Zhang Z, Ma X, Sheng W, Zhu J, Cai G, Cai G, Liu M, Gu W, Li J: A pilot study of biological markers (BM) as predictors for response and prognosis in patients (pts) with R0 resected gastric cancer (GC). J Clin Oncol; 2009 May 20;27(15_suppl):e22076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22076 Background: To evaluate clinical value of biological markers and their prognostic significance in gastric cancer as well as prediction to clinic outcome; To select preference marker for targeted therapy in high risk patients hence to guide personalized treatment.
  • Preoperative tumor markers include: CEA, AFP, CA199, CA50, CA72-4, CA24-2 and postoperative immunohistochemical examination include: Bax, Bcl-2, P27, CyclinD1, TOPO2, MDR, GST-π, Ki67, AgNOR, EGFR, P21, P53, PCNA, C-myc and Neu were analyzed.
  • Logistic regression analysis showed bcl-2, ki67, c-myc2 and Neu were relative with more nodal involvement.
  • There were different clinical significance with those biomarkers.
  • Univariate analysis showed that clinical staging, level of cyclinD1 and CEA were correlated with OS (p<0.05).
  • CONCLUSIONS: Biological markers may be helpful in predicting the clinical outcome and prognosis for R0 resected gastric cancer patients.
  • Further study are needed to confirm their clinical significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963218.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, Krivoshik AP: Ongoing phase I studies of ABT-263: Mitigating Bcl-X&lt;sub&gt;L&lt;/sub&gt; induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol; 2009 May 20;27(15_suppl):3505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing phase I studies of ABT-263: Mitigating Bcl-X<sub>L</sub> induced thrombocytopenia with lead-in and continuous dosing.
  • : 3505 Background: ABT-263, a novel, oral BH3 mimetic, potently inhibits multiple antiapoptotic Bcl-2 family proteins.
  • Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).
  • However, thrombocytopenia (TCP) due to on-target Bcl-X<sub>L</sub> inhibition-induced platelet apoptosis is also observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Novais PC, Paula AA, Rodrigues AA Jr, Barione DF, Peria FM, Tirapelli DP, Tucci S Jr, Cologna AJ, Martins AC, Tirapelli LF: Apoptotic genes as a prognostic factor in penile epidermoid carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22208

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comprehension of the disease behavior can provides new, non-invasive therapeutic interventions.
  • For this reason, the protein expression of apoptotic genes (caspase-3, caspase-8, bcl-2) were analysed with the immunohistochemistry technique, correlating with tumor grade (I, II and III) and with the patient survival in order to understand the basic mechanism of tumoral transformation.
  • Therefore, this study can contribute with information about this disease.
  • METHODS: The immunohistochemistry reactions on 50 samples of squamous cell carcinoma were carried out with the avidina-biotina-imunoperoxidase method with antigen recovery.
  • The analyses were made using the graduation method 'in crosses' (0 to 4 crosses - no stain to more than 75% of positives cells) and in categories (low, intermediate, high) of the cytoplasm immunoreactivity of the epidermoide penile carcinoma cells.
  • The protein expression of caspase-3 and caspase-8 was lesser in relation to bcl-2, suggesting that the apoptotics rate in this carcinoma is low.
  • The higher expression of the anti-apoptotic protein bcl-2 suggests a higher preservation of the tumoral cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964136.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Braun E, Katz D, Venugopal P, Larson M, Shammo J, Fung H, Gregory S: Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy.
  • : e19529 Background: Radioimmunotherapy is a therapeutic option for relapsed or refractory indolent, follicular and transformed non Hodgkin's lymphoma and mantle cell lymphoma.
  • Groups characteristics such as sex, type of RIT, presence of disease in bone marrow, FLIPI/IPI and use of G-CSF were noted.
  • CONCLUSIONS: RIT should be considered a safe therapeutic modality in patients with refractory or relapsed indolent, follicular, NHL, transformed and Mantle Cell lymphoma regardless of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • The aim of this study was to compare the time of engraftment and mortality rate and cost of neutropenic treatment in outpatient versus inpatient autologous stem cell transplantation (SCT).
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.
  • CONCLUSIONS: Results show that out-patient autologous SCT in malignant hematologic disorders is feasible and comparable with inpatient protocol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE: Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.
  • : 8508 Background: A prior pilot study of epratuzumab (Immunomedics) and rituximab in combination with CHOP chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Vaseemuddin M, Sam R: Large B-cell non-Hodgkin lymphoma. Am J Kidney Dis; 2005 Dec;46(6):A52, e101-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315353.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


25. Blum KA, Smith M, Fung H, Zalevsky J, Combs D, Ramies DA, Younes A: Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol; 2009 May 20;27(15_suppl):8531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.
  • : 8531 Background: XmAb2513 is a novel 2<sup>nd</sup>-generation humanized monoclonal antibody (mAb) directed against CD30 (a cell surface antigen expressed on Reed-Sternberg cells of HL and ALCL), with an Fc region engineered to have increased binding affinity to Fcγ receptors (FcγRs) leading to improved FcγR-dependent effector cell functions.
  • PK parameters appeared non-linear across the dose range from 0.3 - 3 mg/kg.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vergine M, Martino G, Santucci E, Cardarelli A, Palmieri A, La Gumina G, Macrina N, Pasta V: [Cutaneous B-cell non-Hodgkin lymphoma: clinical aspects, diagnostic and surgical approach]. G Chir; 2008 Jun-Jul;29(6-7):281-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous B-cell non-Hodgkin lymphoma: clinical aspects, diagnostic and surgical approach].
  • [Transliterated title] Linfoma cutaneo non Hodgkin a immunofenotipo B: clinica, orientamento diagnostico e chirurgico.
  • By clinical observation and surgical treatment of a patient with cutaneous B-cell non-Hodgkin lymphoma, the Authors describe the nosological approach, the correct diagnosis and the surgical treatment in this disease.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544265.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Girtovitis F, Papadopoulos A, Ntaios G, Kaloutsi V, Kotoula V, Kaiafa G: Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia. Intern Med J; 2009 Aug;39(8):550-3
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia.
  • The coexistence of chronic active hepatitis C with cryoglobulinemia and B-cell lymphoma has been presented in numerous case reports.
  • However, the combination of these conditions with T-cell lymphoma has never been described before.
  • We present the case of a patient who suffered chronic active hepatitis C, cryoglobulinaemia and B-cell lymphoma and was later complicated by cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Cryoglobulinemia / complications. Hepatitis C, Chronic / complications. Lymphoma, B-Cell / complications. Lymphoma, T-Cell, Cutaneous / complications
  • [MeSH-minor] Adult. Bone Marrow Neoplasms / complications. Bone Marrow Neoplasms / virology. Female. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Kidney Neoplasms / virology. Liver Neoplasms / complications. Liver Neoplasms / virology. Skin Neoplasms / complications. Skin Neoplasms / virology


28. Cunningham D, Smith P, Mouncey P, Qian W, Pocock C, Ardeshna KM, Radford J, Davies J, McMillan A, Linch D: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.
  • : 8506 Background: The addition of rituximab to standard therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP21) has resulted in improved survival outcomes in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL).
  • Patient characteristics in the R-CHOP21 and R-CHOP14 arms are; IPI score of ≥4 17%:15%, stage III/IV disease 63%:62%, B symptoms 44%:47%, bulk disease 51%:48%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE: Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res; 2007 Apr;149(4):231-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • The goal of this study was to evaluate the frequency of monoclonal serum FLC in patients with other B-cell malignancies.
  • Frozen sera from 226 patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) were tested for M-protein by the serum FLC assay and compared with standard protein electrophoresis (PEL) and immunofixation (IF).
  • Within NHL, the highest incidences of FLC presence were in patients with mantle cell (36%) and small lymphocytic (24%).
  • Future studies are warranted to elucidate the role of serum FLC as biomarkers of disease, for monitoring of minimal residual disease, and as a prognostic factor for response and survival.
  • [MeSH-major] Immunoglobulin Light Chains / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383597.001).
  • [ISSN] 1931-5244
  • [Journal-full-title] Translational research : the journal of laboratory and clinical medicine
  • [ISO-abbreviation] Transl Res
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin M
  •  go-up   go-down


30. Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y: Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol; 2010 Aug;21(8):1699-705
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events.
  • BACKGROUND: Clinical significance of delayed-onset neutropenia (DON) after autologous hematopoietic stem-cell transplantation (ASCT) has not been well described.
  • We conducted a retrospective cohort study to examine risk factors and clinical impact of DON.
  • DESIGN AND METHODS: Subjects were consecutive 108 patients with B-cell lymphoma receiving ASCT.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20172906.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D'adamo F, Guiducci B, Bernardi D, Barulli S, Piccaluga P, Rocchi M, Isidori A: R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma; 2008 Jun;49(6):1081-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.
  • We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma.
  • Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled.
  • With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease.
  • In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Frail Elderly. Humans. Lymphoma, Follicular / drug therapy. Male. Maximum Tolerated Dose. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prognosis. Prospective Studies. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569635.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


32. van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM, Simic A, Laughlin MJ, Gerson SL, Koç ON: Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol; 2006 Jan;132(1):42-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
  • We investigated the feasibility, safety and efficacy of two B-cell purging methods in patients with CD20+ non-Hodgkin lymphoma (NHL) receiving autologous stsem cell transplantation.
  • Twenty-seven patients were randomised to either in vivo purging with rituximab or ex vivo purging by CD34+ cell selection.
  • Both purging methods were efficient at eliminating B-cells in infusates.
  • When compared with in vivo purging, ex vivo purging was associated with CD34+ cell loss and delayed median neutrophil (10 d vs. 11 d) and platelet (12.5 d vs. 17 d) count recoveries.
  • In conclusion, although both purging methods were feasible and safe, rituximab purging was superior as it did not impair CD34+ cell mobilisation and was associated with faster myeloid recovery.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow Purging / methods. Lymphoma, B-Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD34 / analysis. Feasibility Studies. Female. Hematopoietic Stem Cell Mobilization / methods. Humans. Immunomagnetic Separation / methods. Leukapheresis / methods. Male. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371019.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA43703
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM: Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res; 2009 Oct 15;15(20):6446-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
  • PURPOSE: The growth of non-Hodgkin lymphomas can be influenced by tumor-immune system interactions.
  • Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator of T-cell activation that serves to dampen antitumor immune responses.
  • Blocking anti-CTLA-4 monoclonal antibodies improves host resistance to immunogenic tumors, and the anti-CTLA-4 antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, and ovarian cancers.
  • EXPERIMENTAL DESIGN: We did a phase I trial of ipilimumab in patients with relapsed/refractory B-cell lymphoma to evaluate safety, immunologic activity, and potential clinical efficacy.
  • Two patients had clinical responses; one patient with diffuse large B-cell lymphoma had an ongoing complete response (>31 months), and one with follicular lymphoma had a partial response lasting 19 months.
  • In 5 of 16 cases tested (31%), T-cell proliferation to recall antigens was significantly increased (>2-fold) after ipilimumab therapy.
  • CONCLUSIONS: Blockade of CTLA-4 signaling with the use of ipilimumab is well tolerated at the doses used and has antitumor activity in patients with B-cell lymphoma.
  • Further evaluation of ipilimumab alone or in combination with other agents in B-cell lymphoma patients is therefore warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103 [9223321.001]
  • [Cites] Immunity. 1997 Apr;6(4):411-7 [9133420.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1184-90 [9694706.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 [10500201.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] Blood. 2005 Jan 1;105(1):13-21 [15353480.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):432-40 [16093791.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):958-64 [17289891.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1810-5 [17363537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5275-83 [18838703.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5950-6 [19018089.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1581-8 [18974373.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1075-81 [19139427.001]
  • [Cites] Immunity. 1999 Oct;11(4):483-93 [10549630.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] Immunity. 2001 Feb;14(2):145-55 [11239447.001]
  • [Cites] Annu Rev Immunol. 2001;19:565-94 [11244047.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1517-26 [11861263.001]
  • [Cites] Eur J Immunol. 2002 Apr;32(4):972-81 [11920563.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):444-55 [12841382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2093-9 [7427915.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] Annu Rev Immunol. 1996;14:233-58 [8717514.001]
  • [Cites] Immunol Rev. 1996 Oct;153:27-46 [9010718.001]
  • [Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4036-41 [9307290.001]
  • (PMID = 19808874.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA108182-02; United States / NCI NIH HHS / CA / U01 CA069912; United States / NCI NIH HHS / CA / U01 CA069912-15; United States / NCI NIH HHS / CA / R21 CA108182; United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 6T8C155666 / ipilimumab
  • [Other-IDs] NLM/ NIHMS140341; NLM/ PMC2763019
  •  go-up   go-down


34. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C: Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.
  • : 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.
  • Twelve pts (35%) had history of BM involvement with lymphoma.
  • At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).
  • RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10<sup>8</sup> (range 0.25-58.0) and 1.6 x 10<sup>6</sup> (range 0.03-5.8), respectively.
  • Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%).
  • Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Soufla G, Baritaki S, Sifakis S, Zafiropulos A, Spandidos DA: Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. Int J Biol Markers; 2005 Jan - Mar;20(1):18-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
  • : Deregulation of the apoptotic machinery plays a major role in cell death, cellular transformation and cancer. p53, Bcl-2, Bcl-XL, Bax and Mdm2 mRNA expression patterns were evaluated in tissue samples with cervical intraepithelial neoplasia (CIN) and cervical cancer compared to those of normal cervical tissues, and correlated with the underlying cervical lesions.
  • Transcript levels of the above genes were assessed by RT-PCR analysis in a total of 44 cervical specimens. p53, Bcl-2, Bax and Mdm2 transcript levels were significantly different in the normal, CIN and cancer specimen groups (p=0.003, p=0.009, p=0.040 and p=0.001, respectively).
  • Specifically, p53, Bax and Bcl-2 exhibited substantially lower transcript levels in CIN lesions compared to controls, whereas Bax mRNA levels showed a significant decrease in cancer compared to normal specimens.
  • High-grade squamous intraepithelial lesions exhibited lower p53 and Bcl-2 mRNA levels than controls (p=0.002, p=0.016).
  • Coexpression analysis revealed more correlations between the above apoptosis-related molecules in normal tissues compared to CIN or cancer specimens. p53 showed significant coexpression with Bax, Bcl-2 and Mdm2 (p=0.040, p=0.013 and p=0.015, respectively) in normal cervical specimens.
  • Bax and Bcl-XL mRNA expression was negatively correlated.
  • Mdm2 transcriptional levels correlated significantly with those of Bax, Bcl-XL and Bcl-2.
  • Our findings show that p53, Bax, Bcl-2 and Mdm2 mRNA expression levels correlate with the malignant transformation of the uterine cervix. mRNA coexpression patterns of the members of the pro- and anti-apoptotic family examined in cervical carcinogenesis were found to be disrupted in CIN and cancer, as already demonstrated at the protein level. (Int J Biol Markers 2005; 20: 18-27).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207100.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Fiveash JB, Chowdhary SA, Peereboom D Jr, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2010 Background: R-(-)-gossypol (AT-101) is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins.
  • A prior study of racemic gossypol demonstrated objective responses in patients with malignant glioma.
  • METHODS: Fifty-six patients with recurrent GBM were enrolled in this multi-institution phase II clinical trial through the NABTT CNS consortium designed to detect a 33% increase in overall survival (OS, primary endpoint) from 5 to 6.65 months with Power/Alpha 80%/0.01.
  • Seven patients (16%) had stable disease as the best response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Pitot HC, Mould D, Maleski J, Leopold L: Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2557 Background: AT-101 is an oral, pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, Mcl-1).
  • Overexpression of Bcl-2 family proteins is common in human cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961871.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • 8 patients (32%) had stable disease and 12 (48%) progressed on treatment.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • It can mitigate symptoms resulting from bulky disease and shows potential as a palliative treatment option.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • Initial trials of the oral, pan-Bcl-2 inhibitor AT-101 showed acute dose limiting toxicity of Gr 3-4 AST/ALT (MTD 40 mg/d) and ileus with prolonged dosing daily (QD) for 21/28 days per cycle (Saleh, NCI/EORTC, 2005; James, ASCO, 2006 and Saleh, ASCO, 2007).
  • Stable disease was reported in 13/37 (35%) pts.
  • One pt with NSCLC continues on study with stable disease for 33 cycles and 2 additional pts were on study with stable disease for 18 and 9 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Doudican NA, Pennell R, Tu T, Liebes L, Pavlick A, Berman R, Shapiro R, Goldberg JD, Osman I, Orlow S: Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2. J Clin Oncol; 2009 May 20;27(15_suppl):9075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2.
  • : 9075 Background: Defects in apoptosis are thought to contribute to melanoma chemoresistance, making the anti-apoptotic protein Bcl-2 an attractive therapeutic target.
  • We identified mebendazole (MBZ), a microtubule binding agent, as an inducer of melanoma cytotoxicity via a Bcl-2 dependent mechanism in vitro (Mol Cancer Res, Aug 2008).
  • In the present study, we assessed the effect of MBZ on human melanoma tumor growth and progression in a mouse xenograft model and compared the ability of MBZ to inhibit growth of cultured melanoma cells to that of oblimersen (OBL), an antisense drug targeting Bcl-2.
  • Bcl-2 phosphorylation was determined by immunoblotting.
  • This reduction in volume was accompanied by a 46% decrease in proliferating cells and an 81% increase in apoptotic cells.
  • Orally administered MBZ treatment resulted in Bcl-2 phosphorylation in vivo, further confirming its mechanism of action.
  • MBZ inhibited growth of melanoma cells in culture more effectively than OBL with GI50 values of 0.32 uM and 7.45 uM, respectively.
  • A phase II clinical trial investigating MBZ's utility as adjuvant therapy in patients with stage IV, resected melanoma is planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T: Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol; 2009 May 20;27(15_suppl):e19504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003).
  • : e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis.
  • A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL.
  • A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease.
  • METHODS: Patients received 25 mg oral lenalidomide once daily on days 1-21 of every 28-day cycle and continued therapy until disease progression or toxicity.
  • Median time from diagnosis was 2 years (0.4-18.6), patients had received a median of 3 prior treatment regimens (1-10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS: Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):8576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.
  • : 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading to regulation of gene transcription and other cellular processes.
  • LBH589 is a novel and potent DAC class I and II Inhibitor undergoing pre-clinical and clinical testing.
  • In order to develop therapeutic options for refractory/resistant B-cell lymphomas we studied the effects of LBH589 in the anti-tumor activity of chemotherapy agents and monoclonal antibodies in a panel of rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), and in lymphoma cells isolated from patients with treatment-naïve or refractory/relapsed B-cell lymphomas by negative selection using magnetic beads.
  • NHL cells lines were exposed to the following chemotherapy agents or monoclonal antibodies: CDDP, doxorubicin, vincristine, bortezomib or rituximab, veltuzumab, or isotype, alone or in combination with LBH589.
  • Patient-derived tumor cells were exposed to either LBH589, bortezomib or both.
  • Changes in ATP content were determined by cell titer glow assay.
  • RNA was isolated from NHL cell lines exposed to LBH859 and changes in gene expression of the Bcl-2 family members were determined by qualitative polymerase chain reaction (PCR).
  • LBH589 was active as a single agent against RSCL, RRCL or patient-derived tumor cells.
  • In addition, Bcl-XL gene down-regulation was observed following exposure to LBH859.
  • Our data suggests that LBH589 is active against various RSCL, RRCL and patient-derived tumor cells.
  • Findings suggest that LBH589 added to systemic anti-CD20 and/or chemotherapy could result in a novel and potent treatment strategy against B-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Jeevangi N, Joshi A, Shah M, Kannan S, Gupta S, Nair R, Khattry N: Results of autologous transplants for lymphomas from a tertiary cancer center in India. J Clin Oncol; 2009 May 20;27(15_suppl):7106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of autologous transplants for lymphomas from a tertiary cancer center in India.
  • : 7106 Background: Autologous stem cell transplanation is the standard of care for patients of relapsed and refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).
  • We report the results of transplants in lymphomas from our center and role of possible prognostic factors.
  • Seventy eight percent of patients received peripheral blood stem cells (PBSC), 8% bone marrow (BM) and 14% both PBSC and BM.
  • Prognostic factors evaluated for progression free survival (PFS) were serum albumin level and body mass index (BMI) at the time of transplant, stage at diagnosis and source of stem cells, while for over all survival (OS), status of disease at transplant was also included.
  • RESULTS: The median time to transplant was 2.25 years from the time of diagnosis.
  • At the time of transplant, thirty two percent were in complete remission (CR), 50% in partial remission (PR) and 18% had refractory disease (RD).
  • The best disease response rate was 86% (CR+PR) in patients evaluable for response.
  • CONCLUSIONS: These data provide the first published report of outcomes of autologous transplants in lymphomas from India.
  • Our data suggests that serum albumin level at the time of transplant and stem cell source are important prognostic factors for PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
  • : 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.
  • This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.
  • METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.
  • Significant induction of histone (H3) acetylation was observed in peripheral white blood cells, which lasted for 2-3 days in most pts after single dosing.
  • 4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.
  • CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly.
  • : e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification.
  • AIM: The goal of this study was to evaluate clinical characteristics and survival of EBV positive diffuse large B cell lymphoma of the elderly from Peruvian patients.
  • METHODS: Between January 2002 and June 2008, eleven patients with EBV positive diffuse large B cell lymphoma of the elderly were included in the analysis.
  • All cases were positive to the presence of EBV encoded RNA (EBER) by CISH and CD20 and/or Pax-5 expression by immunohistochemistry.Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of BCL6, CD10, CD30 and MUM-1/IRF4 by tissue microarray (TMA) technique..
  • Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).
  • Ten cases (83%) were of the Non-GC and 1 case was GC.
  • Complete response (n=2), partial response (n=0) and progressive disease (n=3).
  • CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.
  • It is the first report of this entity in a non-Asian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Gillet JP, Molina TJ, Jamart J, Gaulard P, Leroy K, Briere J, Theate I, Thieblemont C, Bosly A, Herin M, Hamels J, Remacle J: Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. Leuk Lymphoma; 2009 Mar;50(3):410-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis.
  • Lymphomas are classified according to the World Health Organisation (WHO) classification which defines subtypes on the basis of clinical, morphological, immunophenotypic, molecular and cytogenetic criteria.
  • Differential diagnosis of the subtypes is sometimes difficult, especially for small B-cell lymphoma (SBCL).
  • Standardisation of molecular genetic assays using multiple gene expression analysis by microarrays could be a useful complement to the current diagnosis.
  • The aim of the present study was to develop a low density DNA microarray for the analysis of 107 genes associated with B-cell non-Hodgkin lymphoma and to evaluate its performance in the diagnosis of SBCL.
  • A predictive tool based on Fisher discriminant analysis using a training set of 40 patients including four different subtypes (follicular lymphoma n = 15, mantle cell lymphoma n = 7, B-cell chronic lymphocytic leukemia n = 6 and splenic marginal zone lymphoma n = 12) was designed.
  • This pilot study demonstrates that such a microarray tool may be a promising diagnostic approach for small B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / diagnosis. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Artificial Intelligence. Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Pilot Projects. RNA, Neoplasm / analysis. RNA, Neoplasm / isolation & purification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294557.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


47. Levine B, Sinha SC, Kroemer G: Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy; 2008 Jul 01;4(5):600-606
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 family members: Dual regulators of apoptosis and autophagy.
  • In normal conditions, Beclin 1 is bound to and inhibited by Bcl-2 or the Bcl-2 homolog Bcl-X<sub>L</sub>.
  • This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X<sub>L</sub>.
  • Other proteins containing BH3 domains, called BH3-only proteins, can competitively disrupt the interaction between Beclin 1 and Bcl-2/Bcl-X<sub>L</sub> to induce autophagy.
  • Nutrient starvation, which is a potent physiologic inducer of autophagy, can stimulate the dissociation of Beclin 1 from its inhibitors, either by activating BH3-only proteins (such as Bad) or by posttranslational modifications of Bcl-2 (such as phosphorylation) that may reduce its affinity for Beclin 1 and BH3-only proteins.
  • Thus, anti-apoptotic Bcl-2 family members and pro-apoptotic BH3-only proteins may participate in the inhibition and induction of autophagy, respectively.
  • This hitherto neglected crosstalk between the core machineries regulating autophagy and apoptosis may redefine the role of Bcl-2 family proteins in oncogenesis and tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28186856.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade ≥3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • This facilitated MTD finding with fewer pts given prior data on B+RCHOP.
  • 6 pts (55%) had stage IV disease; 8 (64%) had FLIPI ≥2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • Median age at diagnosis was 60 (15-83).
  • 52 (73%) were DLBCL, 11 (16%) were T-cell, 8 (11%) were MALT.
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • 35 (67%) patients with DLBCL are alive & disease free.
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • All deaths in the T cell group were due to progressive disease.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I: [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. Gastroenterol Hepatol; 2010 May;33(5):377-81
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
  • [Transliterated title] Reactivación de la hepatitis B en un paciente HBsAg negativo/antiHBc positivo con linfoma B que recibió quimioterapia con rituximab.
  • We present the case of a patient with B-cell non-Hodgkin lymphoma receiving combination chemotherapy with rituximab who showed hepatitis B reactivation followed by liver failure.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Hepatitis B Antibodies / blood. Hepatitis B Core Antigens / immunology. Hepatitis B virus / physiology. Hepatitis B, Chronic / complications. Immunologic Factors / adverse effects. Immunotherapy / adverse effects. Lymphoma, B-Cell, Marginal Zone / complications. Virus Activation / drug effects. Virus Activation / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20363054.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens; 0 / Immunologic Factors; 0 / Organophosphonates; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 99YXE507IL / Tenofovir; JAC85A2161 / Adenine; VB0R961HZT / Prednisone; COP protocol 2
  • [Number-of-references] 33
  •  go-up   go-down


51. Ivanov V, Tabouret E, Chuto G, Chetaille B, Fezoui H, Coso D, Rey J, Aurran-Schleinitz T, Schiano JM, Stoppa AM, Blaise D, Bouabdallah R: Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma; 2010 Sep;51(9):1758-60
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629527.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


52. Naina HV, Pruthi RK, Litzow MR, Ansell SM, Dispenzieri A, Hogan WJ, Gertz MA, Elliott MA, Gastineau DA, Kumar SK: Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization.
  • METHODS: Between January 2000 and October 2008, a total of 631 patients underwent peripheral blood stem cell mobilization (PBSCM) using either GCSF, GMCSF, cyclophosphamide, AMD 3100, or with any of the above combination.
  • We included only patients with a diagnosis of AL amyloidosis (AL), multiple myeloma (MM) Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL).
  • Patients' demographic details and diagnosis of VTE were collected from electronic medical records.
  • We found 7 (1.1%) patients with symptomatic VTE occurring between administration of growth factors and stem cell transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Badin F, Hayslip J: Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. Clinicoecon Outcomes Res; 2010;2:37-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.
  • Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma.
  • In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma.
  • More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma's impacts on patient's productivity and their caregivers.
  • We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(14):1781-9 [11549432.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 [11842383.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1292-301 [15700265.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv25-30 [16702181.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):44-8 [12670330.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Haematologica. 2005 May;90(5):661-71 [15921381.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Ann Hematol. 2006 Aug;85(8):530-4 [16639571.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):227-36 [18231908.001]
  • [Cites] Value Health. 2008 Mar-Apr;11(2):221-30 [18380634.001]
  • [Cites] Acta Oncol. 2008;47(6):1029-36 [18607857.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Jun;8(3):166-70 [18650180.001]
  • [Cites] Bone Marrow Transplant. 2009 May;43(9):701-8 [19029963.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD006552 [19370640.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(1):CD004024 [18254036.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Ann Hematol. 2009 Jan;88(1):51-7 [18665360.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5156-64 [18854568.001]
  • [Cites] Psychooncology. 2009 May;18(5):554-9 [18942670.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):889-96 [9404932.001]
  • (PMID = 21935313.001).
  • [ISSN] 1178-6981
  • [Journal-full-title] ClinicoEconomics and outcomes research : CEOR
  • [ISO-abbreviation] Clinicoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3169958
  • [Keywords] NOTNLM ; cost effectiveness / lymphoma / rituximab / safety / transplant
  •  go-up   go-down


54. Vera L, Reategui R, Beltran B, Morales D, Capellino A, Desposorio C, Castillo J: The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.
  • : e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined.
  • METHODS: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008.
  • We reviewed 2502 clinical records.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • 32 patients (67%) had clinical stage III-IV, B symptoms 35 (73%), the International Prognostic Index was low-risk 20 patients (42%), low-intermediate risk 15 patients (31%), high-intermediate risk 10 patients (21%) and high-risk 3 patients (6%).
  • CD4 count lower than 100 cells/uL was 11 patients (23%).
  • The CD4 count median was 184 cells/uL.
  • Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).
  • From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.
  • The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.
  • Only 16 patients (33%) were receiving HAART previously the diagnosis of NHL and 33 patients (68%) received any oncology treatment.
  • Also a high proportion of T-cells lymphomas are found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kim J, Kim E, Sohn B, Yoon D, Yoo C, Kim S, Lee D, Kim S, Lee J, Suh C: BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):7097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients.
  • : 7097 Background: The objective of this study was to compare the efficacy and toxicity of two high-dose regimens for autologous stem cell transplantation (ASCT) in patients with non-Hodgkin's lymphoma (NHL): BEAM (BCNU, etoposide, cytarabine, and melphalan) and BuCyE (busulfan, cyclophosphamide, and etoposide).
  • RESULTS: Median age was 46 years (range: 15-68), and baseline characteristics, such as gender, International Prognostic Index (IPI), age adjusted IPI, stage and status of disease at ASCT, and median number of infused CD 34+cells/kg were well balanced between groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961268.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Vose J, Loberiza F, Armitage J, Bierman P, Bociek R, Dornan D: Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab. J Clin Oncol; 2009 May 20;27(15_suppl):8567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab.
  • : 8567 Background: The addition of rituximab to cyclophosphamide/ doxorubicin/ vincristine/ prednisone (R-CHOP) therapy for diffuse large B-cell lymphoma (DLBCL) has significantly improved the outcome for many patients (pts).
  • In a multivariate analysis for risk of progression or death: FCGR2A : H/H vs. H/R or R/R by treatment type: CHOP-like [RR 0.63 (95% CI 0.37-1.08), p=0.10] and R-CHOP [RR 0.59 (0.36-0.96), p=0.04] and for FCGR3A V/V vs. F/V or F/F by treatment arm: CHOP-like [RR 0.75 (0.36-1.54), p=0.43] and R-CHOP [RR 2.28(0.70-7.44), p=0.17].
  • However, our study also suggests that a trend toward association of certain polymorphisms with clinical outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • The PI3K p110δ isoform is highly expressed in cells of hematopoietic origin and plays a key role in B cell maturation and function.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Robertson MJ, Kline J, Bauman J, Gardner O, Jonak Z, Koch KM, Murray SC, Weisenbach J, Toso J: A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma.
  • When administered as monotherapy in phase I clinical studies, rhIL-18 was safe, well tolerated and induced potent biological responses (e.g.
  • Th1 cytokine production and expression of activation markers on NK, CD8+ and CD4+ cells).
  • METHODS: Patients with CD20+ B cell non-Hodgkin's lymphoma are being given rituximab (375 mg/m2) IV weekly for 4 consecutive weeks in combination with ascending doses of intravenous rhIL-18 (1 to 100 mcg/kg in 6 cohorts of 3 patients each) IV weekly for 12 weeks to identify a dose that is safe and tolerable and gives a maximum biological effect.
  • Eligible patients must have disease which progressed after standard therapy or for which there is no effective standard treatment.
  • The pharmacodynamic response is as expected with a dose-dependent decrease in circulating activated (CD69+) NK cells within 4 hours after completing the rhIL-18 infusion which rebound to pre-dose levels within 2-4 days.
  • Using the International Working Group response criteria for lymphoma, two subjects had complete responses at 10 and 20 mcg/kg, one subject had a partial response at 10 mcg/kg and three subjects had stable disease at 1, 3 and 3 mcg/kg.
  • This study will define the dose level to be used in a future phase II trial evaluating this combination in patients with relapsed or refractory follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B: Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol; 2007 Aug;138(4):502-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
  • Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients.
  • The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months.
  • The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Recombinant Fusion Proteins / therapeutic use. Recurrence. Rituximab. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608763.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


60. Timmerman J, Betting D, Yamada R, Hurvitz S, Steward K, Said J, van Rooijen N, Kafi K: In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.
  • : 8529 Background: The anti-CD20 monoclonal antibody rituximab (R) is a mainstay in the treatment of B cell non-Hodgkin's lymphoma (NHL), exerting anti-tumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and apoptosis induction.
  • Toll-like receptor 9 agonist CpG oligodeoxynucleotides (CpG) are potent activators of ADCC and T cell immunity, and have been studied for anti-NHL effects when administered by systemic or intratumoral routes.
  • METHODS: We utilized an aggressive syngeneic human CD20-expressing murine B cell lymphoma (38C13-huCD20) to study the in vivo augmentation of R efficacy by CpG.
  • Mechanistic studies indicated that both natural killer cells and complement participated in the cure of tumors by intratumoral CpG + R, by increasing tumor cell sensitivity to complement and ADCC lysis, and by augmenting the cytotoxicity of ADCC effectors.
  • To overcome the need for repeated direct intratumoral injections and allow precise targeting of CpG to tumor cells, we chemically linked CpG to R using a cleavable linker.
  • R-CpG conjugate efficiently eradicated an established B cell lymphoma that is fully resistant to single-agent R.
  • Clinical testing of anti-CD20-CpG conjugates against B cell NHL is thus warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Gaffar HA, Elfayomy A, Elmaghraby A, Elnemr MM, Elsawy WH: bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma.
  • To evaluate the combined modality treatment and selective bladder preservation and to evaluate BCL-2 expression that may predict treatment response and survival.
  • METHODS: 66 eligible patients with T2-4a NxM0 transitional cell carcinoma received two courses of gemcitabine and cisplatin followed by 45 Gy of pelvic radiotherapy in 1.8 Gy fractions with concomitant cisplatin.
  • Immunohistochemistry was used to assess the tumor cell expression of BCL-2.
  • Bcl-2 was expressed in 35 (53%) of the patients.
  • Bcl-2 immunoreactivity was inversely correlated with of histological grade (p = 0.0232) and was not correlated with gender distribution (p = 0.4666), the clinical stage (T) (p = 0.4325) or response to treatment (p = 0.6234).
  • No significant difference was noted between the cause-specific survival rate of patients with positive Bcl-2 expression and those with negative BCL-2 expression.
  • CONCLUSIONS: this combined approach of chemotherapy and radiation therapy with bladder preservation should be considered as an option for muscle-invasive transitional cell carcinoma of bladder.
  • Assessment of Bcl-2 protein expression may be used to predict a clinical response to this combined modality approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Lopez R, Gallardo E, Ruibal A, Leon L, Sanchez-Salmon A, Abdulkader I, Gude F, Curiel T, Barandela J, Gayoso L: HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients.
  • WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3.
  • Sections were scored as positive if >10% of cells stained positively.
  • Staining patterns were correlated to clinical variables.
  • RESULTS: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51).
  • HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57).
  • After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. CONCLUSIONS:.
  • 1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963184.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G: Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. J Clin Oncol; 2009 May 20;27(15_suppl):6031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.
  • : 6031 Background: We have previously demonstrated that p16 expression defines a biologically distinct subgroup of oropharyngeal squamous cell cancers (OSCC).
  • Protein expression levels for a panel of 13 markers (EGFR, MET, STAT 3, ERK 1/2, pAkt, PI3Kp85, PI3Kp110, PTEN, p53, Bcl-2, E-cadherin, β-catenin, NFκB) were analyzed using AQUA.
  • p16 positive tumors also expressed higher levels of PTEN (p = 0.0009), PI3Kp110 (p = 0.03), NFκB (p = 0.007), and Bcl-2 (p = 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Wei CC, Peng CT, Chiang IP, Wu KH: Primary B cell non-hodgkin lymphoma of the penis in a child. J Pediatr Hematol Oncol; 2006 Jul;28(7):479-80
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B cell non-hodgkin lymphoma of the penis in a child.
  • Primary malignant lymphoma is uncommon in the lower urinary tract and is especially rare in the penis.
  • Penile lymphoma has been reported in adults but not in children.
  • After surgical biopsy, pathologic examinations showed that the lesion was a B-cell non-Hodgkin lymphoma.
  • Penile lymphoma should be considered when penile masses are found in children.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Penile Neoplasms / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825998.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, Tsuchida M: Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. Leuk Lymphoma; 2008 Apr;49(4):757-62
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
  • From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia up to 18 years of age were enrolled in Tokyo Children's Cancer Study Group (TCCSG) NHL B9604 protocol study.
  • Five-day intensive chemotherapy courses including high-dose methotrexate and high-dose cyclophosphamide were used for localized disease (Groups A and B).
  • High-dose cytarabine was added for advanced disease (Groups C and D).
  • There were three induction failures, eight relapses (three local, four bone marrow (BM), one BM + local), two toxic deaths and two second malignant neoplasm.
  • The TCCSG NHL B9604 protocol achieved an excellent treatment outcome especially in patients with the most advanced disease (Group D: high BM blast cell burden and/or central nervous system involvement).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy


66. Ready N, Potti A, Karaseva N, Orlov S, Luft A, Popovych O, Liu PY, Holmlund JT, Wood BA, Leopold L: AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. J Clin Oncol; 2009 May 20;27(15_suppl):3577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D.
  • A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101.
  • Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines.
  • CONCLUSIONS: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Tawfik O, Garimella R, Tancabelic J, Keighley J, Pinson D, Khan Q, Templeton K: Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective immunohistochemical study of VDR, RXR, Ki-67, and Bcl-2 expression in primary and metastatic osteosarcoma.
  • : e21516 Background: Osteosarcoma (OS) is a highly malignant tumor with a peak incidence in adolescents and young adults.
  • Patient's prognosis is limited to clinical parameters whereas molecular markers of tumor aggression are yet to be identified.
  • METHODS: Immunohistochemical analysis for VDR, RXR, Ki-67, and bcl-2 was performed on 87 OS specimens to evaluate differentiation, proliferation and apoptosis.
  • Clinical data including site of the primary tumor, presence or absence of metastasis, therapeutic regimens, and outcome were recorded.
  • Thirty-five OSs were conventional, 17 chondroblastic, 6 giant cell, 6 fibroblastic, 6 mixed, 3 telangiectatic, and 2 epithelioid variants.
  • None of the tumors studied was immunoreactive for bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Adamia S, Avet-Loiseau H, Amin SB, Moreau P, Minvielle SS, Treon S, Li C, Anderson KC, Munshi N: Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological significance of microRNA profiling in patients with myeloma.
  • : 8539 MicroRNA, a small endogenous RNA regulating specific expressed gene function has been implicated in normal biological processes as well as in malignant transformation.
  • Here we have investigated the role of microRNAs in multiple myeloma (MM) biology, and their influence on prognosis and clinical outcome.
  • We evaluated profiles of 384 microRNAs in CD138+ MM cells from 79 patients with MM, 11 cell lines and 9 healthy donors using qRT-PCR based microRNA array.
  • We detected significant modulation of expression of 61 microRNAs in myeloma cells compared to normal plasma cells.
  • Group A clustered with MM cell lines, indicating more aggressive course of disease.
  • Within B group, second degree node, group B2, clustered with normal plasma cells indicating indolent course.
  • In group A miR585 and let-7f were upregulated 8-12 fold; in group B, all differentially expressed microRNAs were downregulated (p<0.001) compared to normal plasma cells.
  • These modulated miRNAs target critical signaling molecules such as HOX9, c-myc, Bcl-2, SHP1 and SHP2.
  • We further analyzed the effect of microRNA on clinical outcome.
  • Functional analysis by modulating miRNAs 585, 155 and let-7f showed change in levels of predicted genes with consequent biological effect on growth and apoptosis in MM cell line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Passalacqua R, Brighenti M, Naldi N, Potenzoni D, Monica B, Fumagalli M, Lazzarelli S, Caminiti C: Long-term effects of a program of bladder preservation using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Analysis of biologic predictive factors and health-related quality of life (QOL). J Clin Oncol; 2009 May 20;27(15_suppl):e16014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover we investigated whether p53, Ki67, bcl-2, c-erbB-2 protein expression predict the achievement of a complete response (CR).
  • At the response evaluation, pts with biopsy proven residual disease were considered incomplete responders (IR) and underwent immediate cystectomy.
  • Paraffin embedded blocks of the primary tumors were collected and Ki67, p53, bcl-2 and c-erbB-2 protein expression were evaluated in a blind fashion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • In this retrospective study we report our experience dealing with this disease at the National Institute of Oncology.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • The major symptoms at first diagnosis were: nasal obstruction (88.6%), hypoacousia (88.4%), epistaxis (33.3%) and rhinorrhea (15.3%).
  • Clinical examination founded bilateral cervical lymph nodes in 17 cases (65%).
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • After 110 months median flow-up, median disease free and overall survival were not reached.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA: EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer; 2010;5:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.
  • BACKGROUND: B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda.
  • The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL).
  • There has been an increase in incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic.
  • To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.2.
  • To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, Uganda METHOD: Tumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according to the WHO classification.
  • Real time and nested PCR were used for the detection of HIV.The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin lymphoma type during 2008-2009.
  • RESULTS: In this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell lymphomas were EBV positive.
  • None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas showed EBV integration in the lymphoma cells.None of the Burkitt lymphoma biopsies had HIV by PCR.
  • Of the 121 non Hodgkin B cell lymphoma patients with HIV test results, 19% had HIV.
  • However, only 1(0.04%) case of Burkitt lymphoma had HIV.
  • CONCLUSIONS: The majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1991 Jun;5(6):669-74 [1652978.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Rev Epidemiol Sante Publique. 1980 Oct 30;28(3):307-21 [6258200.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 [6315443.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):165-99 [7663046.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):367-74 [9042803.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1026-33 [9308726.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1191-6 [192894.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):388-95 [12845679.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Curr HIV Res. 2004 Jul;2(3):215-21 [15279585.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] PLoS Biol. 2005 Dec;3(12):e404 [16277553.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):817-23 [18436278.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):255-9 [18723390.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):411-20 [19897039.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):479-90 [20051807.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):308-14 [17097130.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] BMC Infect Dis. 2008;8:111 [18706107.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • (PMID = 20591151.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2907314
  •  go-up   go-down


72. van Dam IE, Kater AP, Hart W, van den Born BJ: [Severe anaemia caused by Human Parvovirus B19 infection in a patient with autoimmune haemolytic anaemia and a B-cell non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd; 2008 Jan 19;152(3):153-7
MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe anaemia caused by Human Parvovirus B19 infection in a patient with autoimmune haemolytic anaemia and a B-cell non-Hodgkin lymphoma].
  • [Transliterated title] Ernstige anemie door infectie met het Humaan parvovirus B19 bij een patiënt met een auto-immuun-hemolytische anemie en een B-cel-non-hodgkinlymfoom.
  • A 65-year-old man with a 15-year history of 'leukemicised' low-grade lymphocytic B-cell non-Hodgkin lymphoma with a low-titre of IgM kappa paraprotein was admitted with severe anaemia and reticulocytopenia.
  • This case illustrates that reticulocytopenia in a patient with a haematologic disorder accompanied by a shortened erythrocyte life-span is suggestive for a primary parvovirus infection, especially following a recent transfusion.
  • [MeSH-minor] Aged. Anemia, Hemolytic, Autoimmune / pathology. Humans. Lymphoma, Non-Hodgkin / pathology. Male


73. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A: Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol; 2008 Nov;143(3):355-60
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
  • Oblimersen sodium plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients.
  • Patients with stable disease or objective response were allowed to receive a second course of treatment.
  • Twelve (28%) patients achieved a minimal response or stable disease.
  • Among the 20 patients with follicular lymphoma the ORR was 60% (eight CR, four PR).
  • Three of the responders were refractory to prior treatment with rituximab, and two of the responses occurred in patients who had failed an autologous stem cell transplant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18764869.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / 01/CM17003
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Oligonucleotides, Antisense; 0 / Thionucleotides; 4F4X42SYQ6 / Rituximab; 85J5ZP6YSL / oblimersen
  •  go-up   go-down


74. Carulli G, Stacchini A, Marini A, Ciriello MM, Zucca A, Cannizzo E, Aliberti S, Demurtas A, Novero D, Calcagno L, Callegari T, Petrini M: Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Am J Clin Pathol; 2009 Aug;132(2):186-90; quiz 306
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration.
  • T-cell antigen expression can be observed in B-cell non-Hodgkin lymphoma (B-NHL).
  • Although CD5 is expressed in B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma, the presence of other T-cell antigens is less common.
  • This article reports a retrospective multicenter analysis in which flow cytometry was used to evaluate aberrant CD8 expression on the pathologic B cells of 951 bone marrow samples from patients with various types of B-NHL.
  • In a total of 18 patients, CD8 was coexpressed: 10 had B-CLL; 1, small lymphocytic lymphoma (SLL); 1, marginal zone lymphoma; 1, lymphoplasmacytic lymphoma; 2, diffuse large B-cell lymphoma; and 3, follicular lymphoma.
  • There was a 1.89% overall frequency of CD8 coexpression in which B-CLL/SLL had a higher frequency (3.03%) than did the other B-cell neoplasms (1.18%).
  • [MeSH-major] Antigens, CD8 / biosynthesis. Biomarkers, Tumor / analysis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605812.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, CD8; 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Manzitti C, Barabino A, Bosio V, Gambini C, Battaglia T, Garaventa A: Rhinopharyngeal B-cell non-hodgkin lymphoma: unusual presentation with massive hematemesis. Pediatr Emerg Care; 2007 Apr;23(4):231-3
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhinopharyngeal B-cell non-hodgkin lymphoma: unusual presentation with massive hematemesis.
  • Lymphomas are the third most frequent type of childhood cancer after acute leukemias and brain tumors.
  • Symptoms at diagnosis are extremely different depending on several factors such as histological subtype, disease extent, and site of tumor.
  • [MeSH-major] Hematemesis / etiology. Lymphoma, B-Cell / diagnosis. Nasopharyngeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438436.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S: Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression. J Clin Oncol; 2009 May 20;27(15_suppl):e16019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts has androgen deprivation for stage D2 disease and were followed at 3 month intervals.
  • METHODS: In an IRB approved study,42 pts had adequate tissue preserved between 1992 and 2006 and their charts were reviewed retrospectively.IHC stains to detect tumor expression of S6(ribosomal),p70s6,pTEN,AKT-1,BCL-1(Cyclin D1),VEGF,c-KIT,PDGFR-alpha and PDGFR-beta were performed by US Labs(Irvine,CA).All results were independently evaluated by two pathologists.Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3+) and percentage of cells staining positive(0-3+).The total score was obtained by adding the scores for indensity and the percentage of positive cells,then averaging the resuts obtained by each reader.For the purpose of this study, stain intensity of 0-1+ was considered negative and the intensity of 2-3+ was considered positive.A Cox regression survival model for each stain was developed with variables known to predict survival :Gleason score,Hemoglobin(Hgb),Alkaline Phosphatase(Alk Phos),Prostate Specific Antigen(PSA),Lactate Dehydrogenase(LDH) levels.
  • CONCLUSIONS: In this small sample of pts, overexpression of S6,p70s6,AKT-1,BCL-1,VEGF,c-KIT,PDGFR-alpha and PDGFR-beta by IHC staining did not predict survival independently.The pTEN staining,however was strong predictor of survival in the multivariate analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. De La Mota J, Thomas B, Fengwei W, Micaily B, Yajue H, Hernandez E: Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):e16578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC).
  • We sought to identify surgical and IC risk factors for metastatic disease.
  • RESULTS: Of the 35 patients identified, 25 (71%) had squamous cell, 9 (26%) adenocarcinoma, and 1 (3%) adenosquamous histology.
  • Immunohistochemical (IC) staining was performed on 29 cases (10 LVI, 4 positive LN) for bcl-2, p53, Ki-67.
  • No correlation was found with p53 or Bcl-2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L: Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol; 2009 May 20;27(15_suppl):9080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9080 Background: Oblimersen (OBL), temozolomide (TMZ), and abraxane (ABX) act synergistically in preclinical studies with melanoma cell lines.
  • Bcl-2 antisense therapy in combination with dacarbazine was encouraging in advanced melanoma patients(pts) with normal LDH.
  • METHODS: Chemotherapy-naïve advanced melanoma pts (ECOG PS ≤ 2, baseline LDH ≤1.1 × ULN, measurable disease per RECIST) were enrolled on a phase I/II protocol.
  • Immunohistochemical (IHC) staining for Bcl-2, Bcl-XL, BAK and caspase 3 was performed in pre- and post-therapy tumor samples.
  • Disease sites included liver (6), other visceral sites (10), skin, subcutaneous tissue, and lymph nodes (2).
  • Shed cryptic epitopes correlated with clinical response versus disease progression.
  • Alteration of the tumor biology based on phenotypic changes in Bcl-2, Bcl-xL, BAK and caspase 3 correlated with response to treatment.
  • Biomarker studies support the rationale that Bcl-2 antisense therapy specifically impacts apoptotic signaling pathways in melanoma cells from metastatic tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Horning SJ, Levy R, Lossos IS, Gascoyne RD, Natkunam Y: Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). J Clin Oncol; 2009 May 20;27(15_suppl):8581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP).
  • : 8581 Background: Diffuse large B cell lymphoma (DLBCL) cells coexpress VEGF, VEGFR1 and VEGFR2.
  • METHODS: 162 pts with de novo DLBCL treated with R-CHOP and median followup of 44 months were evaluated retrospectively with immunohistochemistry on tissue microarrays.
  • Scoring: VEGF, VEGFR1, VEGFR2, and phosphoVEGFR2 (pVEGFR2) in lymphoma cells (categorical variable) <5%, none; 5-30%, weak; >30%, strong.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962266.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Yoo C, Sohn B, Kim J, Yoon D, Huh J, Kim S, Lee D, Kim S, Lee J, Suh C: The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):8570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.
  • : 8570 Background: The combination of rituximab and CHOP chemotherapy (R-CHOP) has improved survival of patients with diffuse large B-cell lymphoma (DLBCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961016.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.
  • : 8509 Background: Salvage chemotherapy followed by high dose therapy and autologous stem cell transplantation (ASCT) is the standard of treatment for chemosensitive relapses in diffuse large B cell lymphoma.
  • Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • : 8582 Background: Bcl-2 family proteins are overexpressed in the majority of patients with FL and contribute to resistance to therapy.
  • AT-101 is a pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and potent inducer of proapoptotic proteins.
  • Endpoints evaluated the response rate (RR) at week 8 (primary), overall response rate (ORR), molecular response rate (BCL-2JH rearrangement in blood and bone marrow), and safety of the combination.
  • RESULTS: 23 pts enrolled: median age 64 yrs; FLIPI 0-5: 0%/17%/65%/13%/4%; Grade 1/2: 61%/39%; bulky disease (>5cm<sup>3</sup>): 35%; stage: 1-4 4%/4%/30%/61%; bone marrow + 48%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Yi J, Kim S, Lee S, Park S, Ko Y, Choi J, Kim W: Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma.
  • : e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL).
  • However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial.
  • METHODS: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed.
  • After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan.
  • Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression.
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • CONCLUSIONS: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I: FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood; 2008 Jan 1;111(1):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.
  • FCRL1 (Fc receptor-like 1) is a cell-surface membrane protein belonging to FCRL family and is preferentially expressed on B cells.
  • To evaluate FcRL1 as an immunotherapy target for B-cell malignancies, we prepared anti-FCRL1 mAbs without cross-reactivity to other FCRL family proteins and analyzed FCRL1 protein expression on malignant cells from patients and on B-cell lines.
  • Frequent FCRL1 expression was observed by flow cytometry on 12 B-cell non-Hodgkin lymphoma (B-NHL) cell lines and many patient samples: 12 of 14 chronic lymphocytic leukemia (CLL), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lymphoma (MCL).
  • Both immunotoxins bound to FCRL1-positive cells with similar affinities (3.4 and 3.2 nM) and were cytotoxic to cell lines, but E9(Fv)-PE38 was 4- to 20-fold more cytotoxic than E3(Fv)-PE38.
  • The concentrations that inhibited response by 50% (IC(50)s) of E9(Fv)-PE38 on 11 different FCRL1-positive cell lines ranged from 1.0 ng/mL to 90 ng/mL and correlated with the FCRL1 expression levels.


86. Kalinka-Warzocha E, Wajs J, Lech-Maranda E, Ceglarek B, Holowiecki J, Federowicz I, Walewski J, Czyz J, Robak T, Warzocha K, Polish Lymphoma Research Group: Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer; 2008 Jul 15;113(2):367-75
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
  • BACKGROUND: The objective of this study was to compare the efficacy of 3 regimens, cladribine alone, cladribine and cyclophosphamide combination, or cyclophosphamide, vincristine, and prednisone combination in previously untreated patients with low-grade B-cell non-Hodgkin lymphoma (LGNHL).
  • Patients for whom all clinical data were available and 162 patients who completed scheduled chemotherapy were analyzed for the endpoints of this study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cladribine / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Poland. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470902.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Investigator] Centkowski P; Sulek K; Blasinska-Morawiec M; Stella-Holowiecka B; Mazur G; Jedrzejczak W; Watek M; Bilinski P; Kisiel E
  •  go-up   go-down


87. Gerecitano JF, O'Connor O, Van Deventer H, Hainsworth J, Leonard J, Afanasayev B, Chen M, Seroogy J, Escandon R, Wolff A, Conlan M: A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):8578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL).
  • : 8578 Background: KSP is a mitotic kinesin essential for cell cycle progression.
  • SB-743921 (SB-921), a selective KSP inhibitor, blocks mitotic spindle assembly with cell cycle arrest in mitosis and cell death.
  • Eligible patients (pts) have relapsed or refractory HL or NHL, aggressive (a) or indolent (i), have had at least 1 prior chemotherapy (CT) regimen, and have relapsed after or were not candidates for stem cell transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962277.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T: Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
  • : e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab.
  • Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y, Kimura A: Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother; 2009 Sep;32(7):737-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
  • T-cell-mediated immunotherapy with a chimeric antigen receptor (CAR) is expected to become a powerful treatment for cancer.
  • CD38, highly expressed in B-cell non-Hodgkin lymphoma (B-NHL) cells, is an attractive target in immunotherapy for B-NHL.
  • We retrovirally transduced a T-cell line, Hut78, expressing little CD38, with an anti-CD38-CAR.
  • Hut78 cells with the anti-CD38-CAR were cocultured with B-NHL cell lines bearing CD38 and also B-NHL cells from patients.
  • Four days later most of the lymphoma cells were killed (the level of cytotoxicity was >95%).
  • By contrast, there was undetectable cytotoxicity against CD38-negative cell lines.
  • Then, we introduced the anti-CD38-CAR into human peripheral T cells.
  • However, the recovery of viable cells was very low, presumably because of an autolytic reaction caused by the association of the anti-CD38-CAR with CD38 on the cell surface.
  • The addition of an anti-CD38 antibody increased the yield of viable transduced T cell probably by blocking the autolytic reaction.
  • We cocultured human peripheral T cells bearing anti-CD38-CAR with B-NHL cells.
  • These cells were injected 4 times into NOD/SCID mice, which were inoculated with B-NHL cells luciferase.
  • By contrast, it increased in all of the mice injected with the mock vector-transduced T cell.
  • In conclusion, T cell with the anti-CD38-CAR showed powerful cytotoxicity against B-NHL cells in vitro and in vivo.
  • These findings may provide an important clue for improving the methodology of T-cell-mediated immunotherapy.
  • [MeSH-major] Antigens, CD38 / immunology. Immunotherapy / methods. Lymphoma, B-Cell / therapy. Receptors, Antigen / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytotoxicity, Immunologic / immunology. Female. Genetic Vectors / genetics. Humans. K562 Cells. Lymphocyte Activation. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Mice. Mice, Inbred NOD. Mice, SCID. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / immunology. Recombinant Fusion Proteins / metabolism. Retroviridae / genetics. Transduction, Genetic. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561535.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen; 0 / Recombinant Fusion Proteins; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


90. Karadeniz C, Oguz A, Citak EC, Uluoglu O, Okur V, Demirci S, Okur A, Aksakal N: Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol; 2007 Sep;24(6):417-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center.
  • The aim of this study was to evaluate and compare the clinical characteristics of the B-cell non-Hodgkin lymphoma (NHL) patients and therapeutic efficacy of modified NHL BFM-90 and NHL BFM-95 protocols in the authors' center.
  • Forty-five patients were treated with modified B-cell BFM-90 and 16 patients were treated with B-cell BFM-95 regimens.
  • Factors associated with lower EFS by univariate analysis were bulky disease, risk groups, and LDH level > or = 500 IU/L.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Allopurinol / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Diuretics / therapeutic use. Female. Fluid Therapy. Hematologic Diseases / chemically induced. Humans. Kaplan-Meier Estimate. L-Lactate Dehydrogenase / blood. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mucositis / chemically induced. Neoplasm Proteins / blood. Risk Assessment. Sodium Bicarbonate / therapeutic use. Survival Analysis. Survival Rate. Treatment Outcome. Tumor Burden. Tumor Lysis Syndrome / prevention & control. Turkey / epidemiology. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710659.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diuretics; 0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 63CZ7GJN5I / Allopurinol; 8MDF5V39QO / Sodium Bicarbonate; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


91. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R, AIDS Malignancy Consortium: Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood; 2010 Apr 15;115(15):3008-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
  • Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL).
  • We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV / physiology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Vincristine / therapeutic use


92. Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A: Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol; 2010 Oct;151(1):37-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
  • Using artificial receptors, it is possible to redirect the specificity of immune cells to tumour-associated antigens, which is expected to provide a useful strategy for cancer immunotherapy.
  • Given that B-cell non-Hodgkin lymphoma (B-NHL) cells invariably express CD19 and CD38, these antigens may be suitable molecular candidates for such immunotherapy.
  • We transduced human peripheral T cells or a T-cell line with either anti-CD19-chimeric receptor (CAR) or anti-CD38-CAR, which contained an anti-CD19 or anti-CD38 antibody-derived single-chain variable domain respectively.
  • Retroviral transduction led to anti-CD19-CAR or anti-CD38-CAR expression in T cells with high efficiency (>60%).
  • The T cell line, Hut78, when transduced with anti-CD19-CAR or anti-CD38-CAR, exerted strong cytotoxicity against the B-NHL cell lines, HT and RL, and lymphoma cells isolated from patients.
  • Interestingly, use of both CARs had an additive cytotoxic effect on HT cells in vitro.
  • In conjunction with rituximab, human peripheral T cells expressing either anti-CD19-CAR or anti-CD38-CAR enhanced cytotoxicity against HT-luciferase cells in xenografted mice.
  • These results provide a powerful rationale for clinical testing of the combination of rituximab with autologous T cells carrying either CAR on aggressive or relapsed B-NHLs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / therapy. Receptors, Antigen / immunology. T-Lymphocytes / transplantation
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / immunology. Antigens, CD38 / immunology. Antigens, Neoplasm / immunology. Cell Death. Combined Modality Therapy. Cytotoxicity, Immunologic. Female. Genetic Vectors. Humans. Immunotherapy / methods. Membrane Glycoproteins / immunology. Mice. Mice, Inbred NOD. Mice, SCID. Retroviridae / genetics. Rituximab. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20678160.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Membrane Glycoproteins; 0 / Receptors, Antigen; 4F4X42SYQ6 / Rituximab; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


93. Gharib AF, Eltarhony SA, Elsawy WH: Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value. J Clin Oncol; 2009 May 20;27(15_suppl):e19539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value.
  • : e19539 Background: CD44 is a cell surface glycoprotein expressed by a large variety of tissues.
  • In addition to their expression on the cell membrane, CD44 proteins are also released from cells, and soluble CD44 proteins are detectable in the normal human circulation.
  • In this prospective study, we investigated the prognostic and clinical value of s-CD44 in patients with aggressive non-Hodgkin's lymphomas.
  • METHODS: s-CD44 concentration was measured in the sera of 64 patients with aggressive non-Hodgkin's lymphomas treated with standard CHOP by using chemiluminescence-enzyme immunoassay (EIA).
  • CONCLUSIONS: Our results showed that a high s-CD44 level before treatment is associated with a high IPI score, poor response to treatment, and unfavorable prognosis in aggressive non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Pienkowska-Grela B, Witkowska A, Grygalewicz B, Rymkiewicz G, Rygier J, Woroniecka R, Walewski J: Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma. Cancer Genet Cytogenet; 2005 Jan 15;156(2):114-21
Genetics Home Reference. consumer health - chromosome 8.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.
  • Translocations involving chromosome 8 are the most common aberrations in B-cell non-Hodgkin lymphoma (B-NHL).
  • The presence of the typical t(8;14)(q24;q32) or its variants has been confirmed in all cases of Burkitt lymphoma (BL), in some cases of Burkitt-like lymphoma (BLL), and in diffuse large B-cell lymphoma (DLBCL).
  • Only two of 5 patients suspected of having BL fulfilled all the criteria for this diagnosis; in the others, chromosome 8 was aberrant, but the absence of C-MYC rearrangement or the results of flow cytometry excluded the diagnosis of BL.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 8. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Banding. Chromosome Mapping. Chromosomes, Human, Pair 14. Female. Flow Cytometry. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Translocation, Genetic. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642390.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X: Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):e19546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL).
  • UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia.
  • OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma.
  • Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Azim HA, Malek RA, Santoro L, Gandini S, Bociek RG, Azim HA Jr: High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview. J Clin Oncol; 2009 May 20;27(15_suppl):e19528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview.
  • : e19528 Background: Aggressive non-Hodgkin's lymphoma represents around 60% of lymphomas in the Western world and even more in Egypt.
  • CHOP has been long been recognized as the standard chemotherapy regimen in this disease.
  • The addition of rituximab (R) to CHOP in the treatment of B-cell subtypes has resulted in a significant improvement in all treatment endpoints.
  • Thus CHOP is still offered to these patients as well as those with T-cell subtypes.
  • METHODS: A MEDLINE and COCHRANE library search was performed using the search terms 'CHOP', 'lymphoma' and 'randomized trials'.
  • Such approach should be considered in patients with aggressive B-cell lymphomas not offered R as well as those with T-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Zajac-Spychała O, Derwich K, Mańkowska M, Konatkowska B, Mańkowski P, Wachowiak J: [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1087-91
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)].
  • INTRODUCTION: The aim of this study was to analyze prognostic factors in patients with diagnosed B-cell non-Hodgkin lymphoma (B-NHL).
  • PATIENTS AND METHODS: The retrospective analysis of 44 children with B-NHL, newly diagnosed and treated at the Clinical Department of Paediatric Oncology, Haematology and Transplantology in Poznań.
  • Three children died due to progression of the disease.
  • Median age at diagnosis of both relapsed and non-relapsed children was 8 years.
  • The mean time of achieving complete remission was 67 days in patients demonstrating relapse and 59 days in non-relapsed patients.
  • In patients with relapse the mean initial serum lactate dehydrogenase (LDH) level was significantly lower than in non-relapsed group.
  • Among relapsed patients, 12 (92%) were EBV-seropositive at diagnosis, whereas only 13 (42%) in the group of non-relapsed patients.
  • In the subgroup of children with primary bone marrow involvement the mean absolute count of lymphoblasts in peripheral blood measured at diagnosis was 38.5 G/L in relapsed children and 5.2 G/L in non-relapsed children.
  • In the studied group EBV-seropositivity and initial lower serum LDH level are suggested to be risk factors of relapse of the lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531831.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


98. Ulaner GA, Colletti PM, Conti PS: B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. Radiology; 2008 Mar;246(3):895-902
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
  • PURPOSE: To retrospectively compare fusion fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET)/computed tomographic (CT) imaging with CT imaging alone in the evaluation of yttrium 90 ((90)Y)-ibritumomab tiuxetan radioimmunotherapy treatment of B-cell non-Hodgkin lymphoma.
  • Five men and five women (mean age, 52 years; range, 38-70 years) with relapsed or refractory non-Hodgkin lymphoma underwent FDG PET/CT imaging both 14-27 days before treatment with (90)Y-ibritumomab tiuxetan and 4-6 months after treatment.
  • Response after treatment was measured with CT imaging as complete response, partial response, or stable or progressive disease, as defined according to published criteria from a National Cancer Institute-sponsored international workshop.
  • Response after treatment was measured with PET as complete response, partial response, or stable or progressive disease, as defined according to published criteria of the European Organization for Research and Treatment of Cancer.
  • Both of these patients were free of evident disease at 18 or more months of follow-up.
  • CONCLUSION: The use of combined FDG PET/CT may enable superior assessment of response to (90)Y-ibritumomab tiuxetan treatment than the use of CT alone, at which one may underestimate (90)Y-ibritumomab tiuxetan response by considering inactive residual CT masses to be residual disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18258810.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


99. Sabet-Peyman EJ, Eberhart CG, Janjua K, Shah SM, Do DV, Nguyen QD: Persistent intermediate uveitis associated with latent manifestation of facial large B-cell non-Hodgkin lymphoma. Ocul Immunol Inflamm; 2009 Sep-Oct;17(5):322-4
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent intermediate uveitis associated with latent manifestation of facial large B-cell non-Hodgkin lymphoma.
  • PURPOSE: To report a case of intraocular non-Hodgkin lymphoma (NHL) manifesting as persistent intermediate uveitis, facial mass, and Bell palsy.
  • [MeSH-major] Eye Neoplasms / complications. Facial Neoplasms / complications. Lymphoma, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Neoplasms, Second Primary / complications. Uveitis, Intermediate / etiology


100. Bertrand P, Courel MN, Maingonnat C, Jardin F, Tilly H, Bastard C: Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer; 2005 Jan 10;113(2):207-12
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness.
  • In this work, HYAL2 mRNA, HA and total hyaluronidases expression were examined in lymphoma tissue extracts and correlated to the lymphoma subtype.
  • Our results showed that HYAL2 mRNA expression was correlated to lymphoma diagnosis (p = 6 x 10(-3)) and was significantly lower in high-grade lymphoma, i.e., diffuse large B-cell diffuse lymphomas (DLBCLs).
  • HA levels also correlated to lymphoma subtype (p = 1 x 10(-5)) and were higher in DLBCLs.
  • Our results suggest that HYAL2 may have a prognostic significance in lymphomas and an antioncogenic activity.
  • Conversely, HA overexpression in high-grade lymphomas is in favor of its involvement in tumor development and could provide a useful target for lymphoma therapy using HA-binding peptides.
  • [MeSH-major] Cell Adhesion Molecules / biosynthesis. Chromosomes, Human, Pair 3. Hyaluronic Acid / biosynthesis. Hyaluronoglucosaminidase / biosynthesis. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Disease Progression. GPI-Linked Proteins. Gene Expression Profiling. Humans. Prognosis. RNA, Messenger / biosynthesis. Receptors, Virus. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Feb 1;120(3):718 [17096331.001]
  • (PMID = 15386412.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / RNA, Messenger; 0 / Receptors, Virus; 9004-61-9 / Hyaluronic Acid; EC 3.2.1.25 / Hyal2 protein, human; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down






Advertisement